Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
   
Ask the Experts About

Choosing Your MedsChoosing Your Meds
          
Rollover images to visit our other forums!
Recent AnswersAsk a Question
  
  • Email Email
  • Glossary Glossary


Improvement time on ART
Jan 31, 2011

I have just begun a clinical trial of truvada + either Viiv's GSK 572 or Raltegravir. After 4 weeks my Viral Load has dropped from 34k to undetectable and CD4's have gone from 345 to 505. I am really happy with the results, and I feel great, but I just wondered whether these types of results are the norm with these combinations and whether the improvement is likely to be sustained or is just a 'blip'?

Response from Dr. McGowan

Congratulations on your great response to treatment.

The study you are on is comparing 2 Integrase Inhibitors. Integrase Inhibitors are known to lead to very rapid declines in HIV viral load. One study has shown that this very rapid drop in viral load can lead to a sooner return of CD4 counts and balance of CD4 to CD8 ratios to normal levels. It certainly is very encouraging.

Best, Joe



Previous
General Question
Next
extreme itching

  
  • Email Email
  • Glossary Glossary

 Get Email Notifications When This Forum Updates or Subscribe With RSS


 
Advertisement



Q&A TERMS OF USE

This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint

Advertisement